tradingkey.logo
搜尋

OptimizeRx Corp

OPRX
添加自選
6.600USD
-0.090-1.35%
交易中 美東報價延遲15分鐘
123.85M總市值
17.87本益比TTM

關於 OptimizeRx Corp 公司

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

OptimizeRx Corp簡介

公司代碼OPRX
公司名稱OptimizeRx Corp
上市日期May 18, 2005
CEOSilvestro (Stephen L)
員工數量106
證券類型Ordinary Share
年結日May 18
公司地址260 Charles Street
城市WALTHAM
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02453
電話12486516558
網址https://www.optimizerx.com/
公司代碼OPRX
上市日期May 18, 2005
CEOSilvestro (Stephen L)

OptimizeRx Corp公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
423.97K
+8.14%
Mr. Stephen L. (Steve) Silvestro
Mr. Stephen L. (Steve) Silvestro
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.51K
-4.90%
Mr. Gregory D. (Greg) Wasson
Mr. Gregory D. (Greg) Wasson
Independent Director
Independent Director
81.83K
+42.18%
Mr. Edward (Ed) Stelmakh
Mr. Edward (Ed) Stelmakh
Chief Financial & Strategic Officer
Chief Financial & Strategic Officer
72.86K
-2.50%
Mr. Patrick D. (Pat) Spangler
Mr. Patrick D. (Pat) Spangler
Independent Director
Independent Director
68.86K
+50.12%
Mr. Doug Besch
Mr. Doug Besch
Chief Product Officer and Chief Technology Officer
Chief Product Officer and Chief Technology Officer
66.88K
-4.03%
Ms. Catherine M. Klema
Ms. Catherine M. Klema
Independent Director
Independent Director
46.27K
+74.60%
Mr. Andy D'Silva
Mr. Andy D'Silva
Chief Business Officer
Chief Business Officer
44.73K
-3.51%
Ms. Theresa Greco
Ms. Theresa Greco
Chief Commercial Officer
Chief Commercial Officer
32.73K
-5.48%
Ms. Lynn O'Connor Vos
Ms. Lynn O'Connor Vos
Independent Chairperson of the Board
Independent Chairperson of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
423.97K
+8.14%
Mr. Stephen L. (Steve) Silvestro
Mr. Stephen L. (Steve) Silvestro
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
106.51K
-4.90%
Mr. Gregory D. (Greg) Wasson
Mr. Gregory D. (Greg) Wasson
Independent Director
Independent Director
81.83K
+42.18%
Mr. Edward (Ed) Stelmakh
Mr. Edward (Ed) Stelmakh
Chief Financial & Strategic Officer
Chief Financial & Strategic Officer
72.86K
-2.50%
Mr. Patrick D. (Pat) Spangler
Mr. Patrick D. (Pat) Spangler
Independent Director
Independent Director
68.86K
+50.12%
Mr. Doug Besch
Mr. Doug Besch
Chief Product Officer and Chief Technology Officer
Chief Product Officer and Chief Technology Officer
66.88K
-4.03%

常見問題

OptimizeRx Corp的前五大股東是誰?

OptimizeRx Corp的前五大股東如下:Mr. James (Jim) Lang

有多少機構持有OptimizeRx Corp(OPRX)的股份?

截至2026Q1,共有300家機構持有OptimizeRx Corp的股份,合計持有的股份價值約為15.47M,占公司總股份的82.46% 。與2025Q4相比,機構持股有所增加,增幅為-5161941.00。
tradingkey.logo
* 參考、分析和交易策略由提供商Trading Central提供,觀點基於分析師的獨立評估和判斷,未考慮投資者的投資目標和財務狀況。
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有